Fig 1: Progestins enhanced the growth of THRB-silenced EC cells. (A) THRA or THRB silencing efficiency in RL95-2 and KLE cells. (B,C) Protein expression of TRa or TRßsilencing in RL95-2 and KLE cells. (D,G) Cell viability after silencing THRA or THRB in RL95-2 and KLE cells. The cells were treated with si-THRA or si-THRB for 48 h and then cultured in fresh media for 24, 48, 72, and 96 h. (E,F) RL95-2 or (H,I) KLE cells were pretreated with si-THRA or si-THRB for 48 h and then treated with 30 µM MPA (E,H) or NOMAc (F,I); meanwhile, 100 nM T3 was added for 48 h to examine cell viability. The cell viability was normalized to the control, which was set at 100%. The results are presented as mean ± SEM of three independent experiments. TRa/THRA, thyroid hormone receptor alpha; TRß/THRB: thyroid hormone receptor beta; si-Ctrl, negative control treated with siRNA solvent; si-THRA, silenced THRA; si-THRB, silenced THRB.